OUR PAH FRANCHISE

OPSUMIT®

Opsumit(macitentan), an orally available endothelin receptor antagonist, resulted from a tailored drug discovery process in Actelion’s laboratories.

TRACLEER®

Tracleer (bosentan), an orally available endothelin receptor antagonist, was the first oral treatment approved for PAH.

Uptravi logo

UPTRAVI®

Uptravi (selexipag), originally discovered and synthesized by Nippon Shinyaku, is the only approved oral, selective IP receptor agonist targeting the prostacyclin pathway in PAH.

VELETRI®

Veletri (epoprostenol for injection), an intravenous prostacyclin, is stable at room temperature (77°F/25°C) for up to 24 hours, removing the need for patients to carry ice packs.

VENTAVIS®

Ventavis (iloprost), an inhaled formulation of iloprost, is a synthetic compound structurally similar to prostacyclin (PGI2). It is marketed by Actelion in the US and by Bayer Healthcare elsewhere.

OUR SPECIALTY PRODUCTS

VALCHLOR®

Valchlor (mechlorethamine) 0.016% gel is applied topically once daily to affected areas of the skin. Valchlor is currently only available in the US and is approved for the t topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

ZAVESCA®

Zavesca (miglustat) available as oral capsules, is a glucosylceramide synthase inhibitor indicated as monotherapy for the treatment of adult patients with mild to moderate type I Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.

In the European Union, Zavesca is also indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C (NP-C) disease, a very rare, invariably progressive and eventually fatal neurodegenerative genetic disorder affecting both children and adults.

Product Leader, Global Operations 

 

"I'm part of a team which develops new therapies for patients who have few options."